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Introduction  
The period of developmental vulnerability begins at conception and extends through gestation, parturition, 
infanthood and adolescence. The World Health Organisation (WHO) acknowledges that children experience 
quantitatively and qualitatively different exposures to chemicals than adults, and that children may be more or 
less sensitive to a chemical than adults [1, 2]. For instance, because of mouthing behaviours, children have 
higher exposure to chemicals through non-dietary ingestion than adults [3, 4], and the possibility exists for 
different metabolism and/or toxicity between different groups due to the immaturity of defense mechanisms that 
are fully developed in adults [1]. Traditional toxicological studies are inappropriate for assessing the results of 
exposure at very low levels during critical periods of development. Biomonitoring data can be used to identify 
where policies should be directed in order to reduce exposure.  
 
Benzophenone-3 (BP-3, or oxybenzone) is a broadband ultraviolet (UV) radiation filter used as a sunscreen and 
photostabiliser in various cosmetic products worldwide. Human health effects from chronic, low-dose exposure 
are unknown, although photosensitivity and eczema following dermal application has been reported [5, 6].  
 
Triclosan (TCS) is a synthetic, broad spectrum antimicrobial agent used in a wide range of personal care 
products, including toothpaste, soaps, and deodorants; as well as being impregnated in some kitchen utensils and 
children’s toys[7]. Exposure for the general population is through dermal application or oral use of products 
containing TCS. TCS is rapidly metabolized and excreted from the human body. Human data provides no 
evidence for genotoxicity or carcinogenicity, although it is a known respiratory and dermal irritant [8]. The 
concern is the potential for the development of TCS-resistant pathogens because of its widespread use [9].  
 
The overall objective of this study was to evaluate the exposure of Australian infants to ubiquitous contaminants 
TCS and BP-3, thereby establishing baseline values in Australia, and to compare these values to the results from 
other population surveys globally.  
 
Materials and methods  
Samples: De-identified urine samples were obtained from Sullivan Nicolaides Pathology (Taringa, Queensland, 
Australia) from surplus stored specimens that had been collected as part of routine pathology testing. Prior to 
pooling, samples were stratified according to age and sex. The age groups were as follows: 0-<0.5, ≥0.5-<1, ≥1-
<1.5, ≥1.5-<2, ≥2-<2.5, ≥2.5-<3, ≥3-<3.5, ≥3.5-<4, ≥4-<4.5, ≥4.5-<5years. 42 pools were created from 294 
individual samples, where each pool contained 7 samples, with replicate pools per strata where sufficient 
samples were available. Adult pools were stratified in larger age brackets, with 28 donors per pool as follows: 
≥15-<30, ≥30-<45, ≥45-<60, ≥60-<75 years, (9 pools from 252 individual samples).  Date of birth, date of 
sample collection, and sex were known for each sample. The mean age of the pool was calculated by taking the 
mean of all ages of donors included in the pool.  
 
Analysis: Analysis of urine samples for TCS and BP-3 was based on a method described previously [10]. 
Briefly, 100uL urine was diluted to 1mL using HPLC-grade milli-Q water, deconjugated using β-glucuronidase 
(Helix pomatia H1) and incubated at 37°C for 8 hours. Samples were injected directly using a Gilson GX-271 
liquid handler, and analysed using online solid phase extraction (SPE). The liquid chromatography tandem mass 
spectrometry (LC-MS/MS) system consisted of a Shimadzu Prominence UFLC coupled to an AB Sciex API 
5500 QTRAP equipped with an APCI (atmospheric pressure chemical ionisation) source. Chromatographic 
separation was achieved using a Syneri Fusion 50×2.00mm, 2.5μm column. For some samples, concentrations 
of target analytes were beyond linear range of calibration curve. These samples were analysed using direct 
injection (i.e. no SPE) with the same chromatographic profile. Quantitation was performed using isotope 
dilution. 
 
Quality control/quality assurance: 
Samples were analysed in multiple batches, with blank levels and limits of reporting (LOR), respectively of 
<LOD and 0.5ng/ml for TCS, and 3.2 and 10ng/ml for BP-3 (three times the concentration of the blanks). No 
blank subtraction was performed. 
Results and Discussion 
Although individual samples were stratified by age and sex prior to pooling, samples were not differentiated 
according to sex for the purposes of this study, because the female data set was incomplete (only 16 of 40 pools 
analysed at time of publication).  
 
Benzophenone-3: BP-3 was detected in all 51samples, with an average concentration of 116ng/ml urine, and a 
range of 20.6-1750ng/ml for infants and 23.3-68.0ng/ml for adults. Figure 1 shows urinary concentration versus 
average age, where each data point represents a single pooled sample (with 7 individuals per pool for <5years, 
and 28 individuals per pool for ≥15-<75years).  
 
 
Figure 1: Concentration of BP-3 in pooled urine samples from children (0-<5 years) and adults (≥15-<75 years) 
(ng/ml urine) 
 
It appears that the concentration of BP-3 increases from approximately the age of two to four years, after which 
the results are scattered. This age range corresponds with the typical age at which children start to attend day 
care centres.  Interestingly, the apparent increase in urinary concentration is seen beyond two years of age, and 
the European Commission recommends not to use BP-3-containing products on infants younger than two years 
as their metabolic processes may be insufficient to process BP-3 and its breakdown products [5].   
 
The United States Centres for Disease Control and Prevention (CDC) National Health and Nutrition 
Examination Survey (NHANES) presents health-related data for 212 chemicals for a nationally-representative 
percentage of the population. The average level of BP-3 from the 2007-08 cohort was 18.3ng/ml, with a 95th 
percentile of 801ng/ml (non creatinine corrected) [11]. The average level in Australian infants is more than 5-
fold higher than the NHANES data set.  
 
It should be noted that the data set is biased in that the pools were created from surplus routine pathology urine 
samples i.e. from non-healthy individuals. The samples were most frequently from individuals suffering from 
urinary tract infections (Peter Hobson, personal communication), in which case their behaviours may have been 
more reserved than normal, for example, less recreation time outdoors (requiring sunscreen). In this instance, the 
urinary concentrations measured in these samples may actually underestimate the levels in general Australian 
population.  
 
Triclosan: TCS was detected in 94% samples, with an average concentration of 58.9ng/ml. The concentration 
ranged from <LOD-449ng/ml for infants, and 47.7-217ng/ml for adults, with the results shown in Figure 2, 
where each data point represents a single pooled sample (with 7 individuals per pool for <5years, and 28 
individuals per pool for ≥15-<75years).  
 
 
Figure 2: Concentration of triclosan (conjugated and un-conjugated) in pooled urine samples from children (0-
<5 years) and adults (≥15-<75 years) (ng/ml urine) 
 
Although the data shows no clear age trends, the levels in the Australian population are more than double those 
reported by NHANES (compare average 15.4ng/ml for American general population [11], with 58.9ng/ml for 
the Australian population).  
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